Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
Clinical trial NCT07169279 · RECRUITING
Trial details
- NCT number
- NCT07169279
- Sponsor
- QED Therapeutics, a BridgeBio company
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-19
- Primary completion
- 2030-03-01
- Enrollment
- 77
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.